Engineering a designer immunotherapy
Abstract
Understanding of the human immune system has fueled development of numerous drugs, categorized as biologics, designed to mimic or inhibit natural immune responses. Recently, immunoengineering has emerged as a distinct discipline aimed at creating increasingly sophisticated therapeutics that can tailor immune responses for increased potency and/or diminished toxicity. On page 1037 of this issue, Sockolosky et al. ( 1 ) test the hypothesis that an engineered interleukin-2 (IL-2)-IL-2 receptor-β (IL-2Rβ) pair can expand effector T cells for cancer immunotherapy while avoiding the toxicities associated with administration of natural IL-2.
- Publication:
-
Science
- Pub Date:
- March 2018
- DOI:
- 10.1126/science.aas9434
- Bibcode:
- 2018Sci...359..990M